The Resilient Investor: Healthcare's Growth and Innovation Potential
06 Jan 2025
Gareth PowellHead of HealthcareGlobal Healthcare Team
With aging populations, biotech breakthroughs, and increasing public focus on health and wellbeing, the healthcare sector plays a vital role in our society.
In this episode of The Resilient Investor, Gareth Powell, Head of Healthcare at Polar Capital, speaks with David Stevenson about the short and long-term potential of the healthcare sector.
From new product cycles to AI-driven transformation and emerging market adoption, Gareth explains why he sees significant opportunities in healthcare as we enter 2025 and beyond.
This podcast was originally produced in conjunction with Doceo for The Resilient Investor.
Some information contained herein has been obtained from third party sources and has not been independently verified by Polar Capital. Neither Polar Capital nor any other party involved makes any express or implied warranties or representations.
The Resilient Investor: Healthcare's Growth and Innovation Potential
Gareth Powell
Head of Healthcare, Global Healthcare Team
With aging populations, biotech breakthroughs, and increasing public focus on health and wellbeing, the healthcare sector plays a vital role in our society.
In this episode of The Resilient Investor, Gareth Powell, Head of Healthcare at Polar Capital, speaks with David Stevenson about the short and long-term potential of the healthcare sector.
From new product cycles to AI-driven transformation and emerging market adoption, Gareth explains why he sees significant opportunities in healthcare as we enter 2025 and beyond.
This podcast was originally produced in conjunction with Doceo for The Resilient Investor.
Some information contained herein has been obtained from third party sources and has not been independently verified by Polar Capital. Neither Polar Capital nor any other party involved makes any express or implied warranties or representations.
Gareth joined Polar Capital in 2007 to set up the Healthcare team. Prior to Polar Capital, Gareth worked at Framlington, where he began his career in investment management in 1999. Soon afterwards, he joined the Healthcare Team in 2001 and helped launch the Framlington Biotech Fund, which he managed from 2004 until his departure.
Gareth studied biochemistry at Oxford, during which time he worked at Yamanouchi, a leading Japanese pharmaceutical company (later to become Astellas). As well as this, Gareth worked for the Oxford Business School and various academic laboratories including the Sir William Dunn School of Pathology and the Wolfson Institute for Biomedical Research.
